Clinical trial
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
NCT02646189 is registered in ClinicalTrials.gov with Replicor Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
- Lead sponsor
- Replicor Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 31, 2011
- Completion date
- August 31, 2013
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.